Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026

Leqembi generated preliminary global sales of JPY 32.2 billion in Q3 2026, producing BioArctic a royalty of SEK 203.8 million. The royalty was approximately 74% higher than BioArctic recorded in Q3 2025; the figures were published by partner Eisai alongside Biogen’s Q3 report.

Analysis

The key read-through is operating leverage at BioArctic: incremental Leqembi adoption can translate into royalty growth without BioArctic having to build a comparable commercial infrastructure. But one quarter’s royalty growth does not establish a durable run rate; the November 25 report should clarify how material this stream is to consolidated results and whether costs or other programs offset it. For Biogen (BIIB), the same uptake is supportive but is only one input to a broader earnings and pipeline story, so the direct equity sensitivity is likely less concentrated.

Over the next 1–3 months, focus on whether prescription growth converts into persistent treatment and broader access—not just initial starts. Infusion capacity, diagnostic throughput, reimbursement, and safety monitoring can constrain adoption. Eli Lilly’s competing Alzheimer’s treatment is a medium-term substitution risk; better efficacy, convenience, or access could shift physician and patient choices. Currency translation also means reported SEK royalties need not track yen sales one-for-one.

The contrarian risk is extrapolating a strong growth rate from a still-developing launch curve. Conversely, if investors discount BioArctic’s royalty stream as a small or uncertain contribution, verified evidence of recurring royalties could matter more to its valuation than to BIIB’s. No valuation or consensus data are supplied, so avoid a price-target claim.

Key Decisions for Investors

• Treat BIOA.B as the more direct adoption exposure; consider a measured long only if the November 25 report confirms royalty durability and improving contribution to consolidated results. Do not extrapolate the reported year-over-year growth rate mechanically.
• Use BIIB as a lower-purity expression of Leqembi uptake rather than a direct proxy for BioArctic’s royalty economics; avoid a pair trade without comparing valuation, product economics, and the rest of Biogen’s earnings outlook.
• Before adding exposure, verify royalty terms, quarterly patient-start and persistence data, access/reimbursement trends, and BioArctic’s other revenue and expense lines. These are the missing inputs to assess earnings sensitivity.
• Falsify the adoption thesis if subsequent sales or royalties stall, treatment persistence/access disappoints, or competing therapy uptake materially displaces Leqembi. Near-term catalyst: BioArctic’s November 25 results; structural risk horizon: 6–18 months.